企业摘要
季度业绩走势
营业收入
营业利润率
市场偏好度
※ 点击图表可查看该月份的AI分析信息。
营业收入
合并
单独
营业利润
合并
单独
净利润
合并
单独
财务信息
保存为Excel
该期间没有财务信息数据。
~
季度
决算
*单位基准小数点第四位以下的数值标记为'0/-0'
财务指标预测
※ 本预测值是基于历史数据的AI简单估算值，可能与实际业绩存在差异。
企业概况
截至2026年6月
Amicogen, Inc., since its establishment on May 29, 2000, has focused on the development and commercialization of various special enzymes for pharmaceutical use, including the CX enzyme needed to manufacture the cephalosporin antibiotic raw material 7-ACA, based on its self-developed molecular gene evolution technology. The company is an industrial bio specialist that has expanded its special enzyme technology into healthcare materials (N-acetylglucosamine, D-chiro-inositol and pinitol, collagen peptide, and collagen tripeptide), a brand business (K-NUTRA), and biopharmaceutical materials (Protein A resin, culture media, and others). Based on its gene evolution technology and metabolic engineering technology, the company has succeeded in commercializing the CX enzyme.
代表理事
Pyo Jjeo
成立日期
2000年5月29日
法人类型
韩国创业板
行业分类
Manufacture of prepared animal feeds and feed additives
法人注册号
19111-0019783
营业执照号
613-81-21213
电话号码
055-759-6161
传真号码
0557596977
公司地址
14-10 Worasan-ro 950beon-gil, Munsan-eup, Jinju-si, Gyeongsangnam-do
产品与服务
评论